Hangzhou Biotest Biotech Co Ltd Working Capital to Net Assets Ratio
Hangzhou Biotest Biotech Co Ltd working capital to net assets ratio. Hangzhou Biotest Biotech Co Ltd (688767) has a Working Capital to Net Assets ratio of 62.1% as of March 2026. Working capital of CN¥1.47 Billion (current assets of CN¥1.58 Billion minus current liabilities of CN¥111.98 Million) is measured against net assets of CN¥2.36 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hangzhou Biotest Biotech Co Ltd (2017–2025)
Working capital to net assets ratio of Hangzhou Biotest Biotech Co Ltd from 2017 to 2025. This chart shows how Hangzhou Biotest Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the ratio stands at 62.1%, reflecting working capital of CN¥1.47 Billion against net assets of CN¥2.36 Billion CNY. See 688767 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Hangzhou Biotest Biotech Co Ltd Working Capital to Net Assets Ratio by Year (2017–2025)
Hangzhou Biotest Biotech Co Ltd working capital to net assets ratio by year from 2017 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Hangzhou Biotest Biotech Co Ltd from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Hangzhou Biotest Biotech Co Ltd assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 63.4% | CN¥1.50 Billion | CN¥2.37 Billion | CN¥1.66 Billion | CN¥157.98 Million | ▼ -7.0 pp |
| 2024 | 70.4% | CN¥1.70 Billion | CN¥2.41 Billion | CN¥1.88 Billion | CN¥178.62 Million | ▼ -9.6 pp |
| 2023 | 80.0% | CN¥1.94 Billion | CN¥2.42 Billion | CN¥2.09 Billion | CN¥149.43 Million | ▼ -0.5 pp |
| 2022 | 80.6% | CN¥2.06 Billion | CN¥2.56 Billion | CN¥2.24 Billion | CN¥171.08 Million | ▼ -0.8 pp |
| 2021 | 81.4% | CN¥1.72 Billion | CN¥2.11 Billion | CN¥2.03 Billion | CN¥317.56 Million | ▲ +18.7 pp |
| 2020 | 62.6% | CN¥277.40 Million | CN¥443.02 Million | CN¥467.99 Million | CN¥190.58 Million | ▲ +41.7 pp |
| 2019 | 20.9% | CN¥26.35 Million | CN¥125.95 Million | CN¥98.35 Million | CN¥72.01 Million | ▼ -9.5 pp |
| 2018 | 30.4% | CN¥29.82 Million | CN¥98.15 Million | CN¥85.67 Million | CN¥55.85 Million | ▲ +6.3 pp |
| 2017 | 24.1% | CN¥19.17 Million | CN¥79.63 Million | CN¥66.25 Million | CN¥47.09 Million | — |